drugset / Trial / NCT00307541

Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

NCT00307541

Phase 3 Completed 120 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

Evaluate the immune response of GSK Biologicals' 10-valent pneumococcal conjugate vaccine one month after completion of a 3-dose primary vaccination course administered at 2, 3, 4 months of age

Timeline

Start
2005-10-27
Primary completion
2006-04-07
Completion
2006-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Synflorix Vaccine